---
title: "生物科技股票在晚期试验结果公布后迅速上涨"
description: "生物科技股票 Celcuity Inc（纳斯达克代码：CELC）在其乳腺癌疗法 gedatolisib 的第三阶段临床试验结果积极后，股价飙升 221%，达到 43.76 美元。该治疗显示出 76% 的疾病进展风险降低。CELC 的交易价格创下历史新高，超过之前的峰值 33.01 美元。尽管期权活动增加，但看跌期权的交易量以九比一的比例超过看涨期权，表明可能存在修正的押注。分析师维持 “买入” 或"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/250444104.md"
published_at: "2025-07-28T14:37:32.000Z"
---

# 生物科技股票在晚期试验结果公布后迅速上涨

> 生物科技股票 Celcuity Inc（纳斯达克代码：CELC）在其乳腺癌疗法 gedatolisib 的第三阶段临床试验结果积极后，股价飙升 221%，达到 43.76 美元。该治疗显示出 76% 的疾病进展风险降低。CELC 的交易价格创下历史新高，超过之前的峰值 33.01 美元。尽管期权活动增加，但看跌期权的交易量以九比一的比例超过看涨期权，表明可能存在修正的押注。分析师维持 “买入” 或 “强力买入” 的评级，但 12 个月的目标价 32 美元现已低于当前水平

Biotech stock **Celcuity Inc (NASDAQ:CELC)** is skyrocketing today, up 221% at $43.76 at last glance, after upbeat phase 3 trial results for its advanced breast cancer therapy, gedatolisib, which it hopes will have Food & Drug Administration (FDA) approval by the end of the year.

The treatment demonstrated a favorable safety profile in comparison to similar drugs, and the triple combo of gedatolisib, Pfizer's (PFE) Ibrance, and AstraZeneca's (AZN) endocrine therapy Faslode reduced the risk of disease progression or death by 76%.

Headed for its best day ever, CELC is trading at record highs after blowing past its previous June 25, 2021 all-time peak of $33.01. The equity is also breaking into positive territory year-over-year.

Celcuity is seeing much more **options activity** than usual, though puts are outweighing calls nine to one as traders appear to bet on a correction. The most popular contract today is the August 25 put, with new positions being bought to open there.

Analysts have yet to chime in, though all eight in coverage already carry a "buy" or "strong buy" rating. The 12-month consensus price target of $32 is now a discount to current levels, however, so bull notes could keep the wind at the equity's back.

### Related Stocks

- [CELC.US - Celcuity](https://longbridge.com/zh-CN/quote/CELC.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Dir Buller Sells 3,000 ($317.1K) Of Celcuity Inc [CELC] | Buller Richard E Director of Celcuity Inc [CELC] filed a Form 4 on December 9, 2025 with the Securities and Exchange Com | [Link](https://longbridge.com/zh-CN/news/269137964.md) |
| Celcuity Inc. Director Richard E. Buller Reports Sale of Common Shares | Richard E. Buller, Director of Celcuity Inc., has reported the sale of common shares of the company. The details of the  | [Link](https://longbridge.com/zh-CN/news/269137759.md) |
| Celcuity Inc. Director David Dalvey Reports Sale of Common Shares | David Dalvey, a Director at Celcuity Inc., reported the sale of common shares of the company. This information was publi | [Link](https://longbridge.com/zh-CN/news/267235804.md) |
| Celcuity (NASDAQ:CELC) Director Sells $2,400,600.00 in Stock | Celcuity, Inc. (NASDAQ:CELC) Director David Dalvey sold 20,000 shares for $2,400,600 on January 27, reducing his ownersh | [Link](https://longbridge.com/zh-CN/news/274217612.md) |
| Celcuity Announces Updated Phase 3 VIKTORIA-1 Trial Results for Gedatolisib in HR+/HER2- Advanced Breast Cancer | Celcuity Inc. announced updated Phase 3 VIKTORIA-1 trial results for gedatolisib in HR+/HER2- advanced breast cancer. Th | [Link](https://longbridge.com/zh-CN/news/267582985.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。